Home
Skip to main content
        

Pharmacy Examining Board 

The Pharmacy Examining Board regulates the following professions. Please click on the appropriate link below for further information.

Executive Director:          Dan Williams

Board Roster

Related Board Information

 

 



As of September 1, 2014, Phar 8.05(4), 8.07(2) and 8.09 were amended to allow electronic prescriptions for
schedule II controlled substances.


On August 28, 2014 the DEA published its final rule in the Federal Register placing Suvorexant into Schedule IV of the Federal Controlled Substances Act. The scheduling action was effective September 29, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to treat
Suvorexant as a Schedule IV effective November 1, 2014.


On August 22, 2014 the DEA published its final rule in the Federal Register rescheduling hydrocodone combination products from Schedule III to Schedule II of the Federal Controlled Substances Act. The scheduling action was effective October 6, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to similarly
reschedule hydrocodone combination products from Schedule III to Schedule II effective November 1, 2014.


On July 2, 2014, the DEA published its final rule in the Federal Register placing tramadol into schedule IV of the federal Controlled Substances Act effective August 18, 2014. The Wisconsin Controlled Substances Board pursuant to s. 961.11(4), Stats took affirmative action to similarly treat tramadol as a
schedule IV controlled substance effective September 1, 2014.


UPDATE:  As of November 1, 2013,
Phar 7.01(1)(e), Wis. Admin. Code, relating to delivery, became effective.